30 citations
,
January 2008 in “The Aging Male” This study found no difference in male pattern baldness between patients with benign prostate hyperplasia and prostate cancer, and no correlation with serum androgen levels.
22 citations
,
August 2014 in “Clinical endocrinology” This study suggests that the use of finasteride for benign prostate hyperplasia may increase the risk of osteoporosis diagnosis, particularly at higher doses.
11 citations
,
June 2020 in “Biomedicines” This study concluded that incorporating the percentage of free PSA and urinary markers improves the accuracy of determining the need for prostate biopsy.
10 citations
,
March 2023 in “Journal of Chemistry” This study identified ten novel compounds that may effectively target steroid 5 alpha-reductase 2 (5αR-2) for potential treatment of benign prostate hyperplasia, exhibiting comparable binding energies to existing drugs like finasteride and dutasteride.
6 citations
,
March 2015 in “Journal of Endocrinological Investigation” This study suggests that using both finasteride and dutasteride may increase the risk of acute coronary syndrome in patients with benign prostate hyperplasia.